Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
The ethical, medical, and system-related obstacles to providing care for prisoners with severe mental illness and the considerations that should guide decisions about isolating them.
A review of a landmark case that determined why and under what circumstances antipsychotic medications can be administered to incarcerated patients with mental illness against their will.
A review of research that found that physicians disciplined by state medical boards were as much as three times more likely than controls to have had a record of unprofessional behavior in medical school.
Suggests to medical students what forms of self-disclosure are acceptable during clinical encounters and when self-disclosure might be interpreted by patients as taking attention away from them.